Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald reiterated its “Overweight” rating on Bioventus and maintained a $15 price target, implying approximately 5.19% upside from the stock’s current price.
• Analyst sentiment remains favorable: five analysts rate Bioventus a Buy and one rates it a Hold, resulting in a consensus “Moderate Buy” rating and an average price target of $16.
• Bioventus reported quarterly EPS of $0.22, matching expectations, on revenue of $153.21 million. The company issued fiscal 2026 EPS guidance of $0.75–$0.79, while institutional investors own 62.94% of its shares.

Bioventus (NASDAQ:BVS - Get Free Report)'s stock had its "overweight" rating restated by Cantor Fitzgerald in a research report issued on Monday,Benzinga reports. They presently have a $15.00 target price on the stock. Cantor Fitzgerald's price target would suggest a potential upside of 5.19% from the company's current price.

BVS has been the topic of several other reports. Weiss Ratings raised Bioventus from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, August 6th. Craig Hallum reaffirmed a "buy" rating and issued a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Bioventus currently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Bioventus Stock Performance

Shares of NASDAQ:BVS opened at $14.26 on Monday. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.63. The firm has a 50 day moving average of $11.36 and a 200 day moving average of $9.91. Bioventus has a 52 week low of $6.26 and a 52 week high of $15.89.

Bioventus (NASDAQ:BVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting analysts' consensus estimates of $0.22. The firm had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts predict that Bioventus will post 0.79 earnings per share for the current fiscal year.

Institutional Trading of Bioventus

A number of hedge funds have recently modified their holdings of BVS. Marshall Wace LLP lifted its position in shares of Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company's stock valued at $2,149,000 after acquiring an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company's stock worth $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in shares of Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company's stock worth $101,000 after buying an additional 1,887 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Bioventus by 8.2% in the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company's stock worth $187,000 after buying an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP boosted its position in Bioventus by 6.0% during the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company's stock worth $513,000 after acquiring an additional 3,909 shares during the last quarter. Hedge funds and other institutional investors own 62.94% of the company's stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source